Target intelligence / Profile preview

Voltage-dependent N-type calcium channel subunit alpha-1B (CaV2.2) (CaV2.2)

Target
CaV2.2
Molecular classification
Ion channel, Voltage-gated ion channel
01

Overview

N-type voltage-gated calcium channels, specifically the pore-forming subunit alpha-1B (CaV2.2), are high-voltage-activated ion channels predominantly localized at presynaptic nerve terminals and dendrites in the central and peripheral nervous systems [1, 5]. They play a pivotal role in converting action potentials into intracellular calcium signals, which trigger the exocytosis of various neurotransmitters, including glutamate, GABA, and substance P [5, 13]. These channels are critical components of the nociceptive pathway, specifically mediating the transmission of pain signals from primary afferent fibers to the dorsal horn of the spinal cord [2, 11]. Dysregulation or overexpression of CaV2.2 has been implicated in chronic and neuropathic pain, as well as neurological disorders such as migraine and myoclonus-dystonia [2, 6, 11]. Pharmacological targeting of these channels primarily involves direct blockade, as seen with the intrathecal peptide analgesic ziconotide, or indirect modulation of channel trafficking and activity by gabapentinoids like pregabalin [3, 9, 15, 21]. Therapeutic development is often challenged by narrow safety windows, as the channels are essential for normal neuronal signaling, leading to potential side effects like dizziness, confusion, and ataxia [3, 5, 21].

Other names
CACNA1BN-type voltage-gated calcium channelCalcium channel, L type, alpha-1 polypeptide isoform 5Brain calcium channel IIIBIII
02

Mechanism of action

Blockade of calcium ion influx into presynaptic terminals, which inhibits the release of pro-nociceptive neurotransmitters such as glutamate and substance P in the dorsal horn of the spinal cord.

03

Biological functions

Signal transductionSynaptic transmissionNeurotransmitter releaseNociceptionSynaptogenesis
04

Disease associations

Chronic painNeuropathic painCancer painMigraineEpilepsy-dyskinesiaMyoclonus-dystoniaLambert-Eaton myasthenic syndrome
05

Safety considerations

Severe neurological side effects (dizziness, confusion, hallucinations)Orthostatic hypotensionSedationAtaxiaRisk of suicidal ideation
06

Interacting drugs

Ziconotide

5 more in the full profile.

07

Biomarkers

N-type calcium channel antibodiesCACNA1B exon 37a splice variant

Beyond the preview

Go deeper on Voltage-dependent N-type calcium channel subunit alpha-1B (CaV2.2) (CaV2.2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Voltage-dependent N-type calcium channel subunit alpha-1B (CaV2.2) (CaV2.2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call